US4665065A
Expired / Lapsed
US
⏱️ 0.0 years remaining
3-pyrazolo(1,5-aαpyridinium cephem compounds
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1985-05-30
•
Granted: 1987-05-12
•
Expires: 2005-05-30
Abstract
Abstract A compound of the formula; ##STR1## wherein R 0 stands for hydrogen atom, nitrogen-containing heterocyclic group, acyl group or amino-protecting group, Z stands for S, S→O, O or CH 2 , R 4 stands for hydrogen atom, methoxy group or formamido group, R 13 stands for hydrogen atom, methyl group, hydroxyl group or halogen atom and A stands for an optionally substituted pyrazol-2-yl group forming a fused ring at the 1,5-position or a physiologically or pharmaceutically acceptable salt or ester thereof. This compound is novel and has excellent antibacterial activity.
Inventors
- 👤 Akio Miyake
- 👤 Masahiro Kondo
- 👤 Masahiko Fujino
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 23:52
CPC Classifications
C; C07; C07D; C07D501/00; C07D501/14; C07D501/16; C07D501/20; C07D501/24; C07D501/38; C07D501/46; C07D519/00; C07D463/00; C07D463/10; C07D463/14; C07D463/16; C07D463/18; C07D463/20; C07D463/22; C07D505/00; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
129 words
A compound of the formula: ##STR80## wherein R o stands for an acyl group of the formula ##STR81## wherein R 1 stands for amino or protected amino group; R 2 stands for hydrogen atom, halogen atom or nitro group; R 3 stands for (i) straight-chain C 1-3 alkyl group, (ii) straight-chain or branched C 1-3 alkyl group substituted with halogen atom, hydroxyl group, C 1-6 alkoxy group, carboxyl group, C 1-6 alkoxycarbonyl group or cyano group, (iii) allyl group or (iv) propargyl group; Z stands for S; R 4 stands for hydrogen atom; R 13 stands for hydrogen atom; and A stands for pyrazolo[1,5-a]pyridinium-3-yl group which can be substituted with hydroxyl group, C 1-6 alkyl group or carboxyl group, or a physiologically or pharmaceutically acceptable salt or ester thereof.
Claim 2
Dependent Claim
129 words
A compound of the formula: ##STR80## wherein R o stands for an acyl group of the formula ##STR81## wherein R 1 stands for amino or protected amino group; R 2 stands for hydrogen atom, halogen atom or nitro group; R 3 stands for (i) straight-chain C 1-3 alkyl group, (ii) straight-chain or branched C 1-3 alkyl group substituted with halogen atom, hydroxyl group, C 1-6 alkoxy group, carboxyl group, C 1-6 alkoxycarbonyl group or cyano group, (iii) allyl group or (iv) propargyl group; Z stands for S; R 4 stands for hydrogen atom; R 13 stands for hydrogen atom; and A stands for pyrazolo[1,5-a]pyridinium-3-yl group which can be substituted with hydroxyl group, C 1-6 alkyl group or carboxyl group, or a physiologically or pharmaceutically acceptable salt or ester thereof.
Claim 3
Dependent Claim
84 words
A compound of the formula ##STR82## wherein R o is a group of the formula ##STR83## in which R 2 denotes hydrogen atom or halogen atom and R 23 denotes C 1-3 alkyl group optionally substituted with halogen atom, hydroxyl group, C 1-6 alkoxy group, carboxyl group, C 1-6 alkoxycarbonyl group or cyano group, and A stands for pyrazolo[1,5-a]pyridinium-3-yl group which may be substituted with hydroxyl group, C 1-6 alkyl group or carboxyl group, or a physiologically or pharmaceutically acceptable salt or ester thereof.
Claim 4
Dependent Claim
84 words
A compound of the formula ##STR82## wherein R o is a group of the formula ##STR83## in which R 2 denotes hydrogen atom or halogen atom and R 23 denotes C 1-3 alkyl group optionally substituted with halogen atom, hydroxyl group, C 1-6 alkoxy group, carboxyl group, C 1-6 alkoxycarbonyl group or cyano group, and A stands for pyrazolo[1,5-a]pyridinium-3-yl group which may be substituted with hydroxyl group, C 1-6 alkyl group or carboxyl group, or a physiologically or pharmaceutically acceptable salt or ester thereof.
Claim 5
Dependent Claim
8 words
A compound according to claim 2, namely 7β-[2-(2-aminothiazol-4-yl)-2(Z)-methoxyiminoacetamido]-3-[(pyrazolo[1,5-a]pyridinium-3-yl)methyl]-3-cephem-4-carboxylate.
Claim 6
Dependent Claim
8 words
A compound according to claim 2, namely 7β-[2-(2-aminothiazol-4-yl)-2(Z)-methoxyiminoacetamido]-3-[(7-methylpyrazolo[1,5-a]pyridinium-3-yl)methyl]-3-cephem-4-carboxylate.
Claim 7
Dependent Claim
8 words
A compound according to claim 2, namely 7β-[2-(2-aminothiazol-4-yl)-2(Z)-(1-carboxy-1-methylethoxyimino)acetamido]-3-[(pyrazolo[1,5-a]pyridinium-3-yl)methyl]-3-cephem-4-carboxylate.
Claim 8
Dependent Claim
8 words
A compound according to claim 2, namely 7β-[2-(2-aminothiazol-4-yl)-2(Z)-methoxyiminoacetamido]-3-[(7-carboxypyrazolo[1,5-a]pyridinium-3-yl)methyl]-3-cephem-4-carboxylate.
Claim 9
Dependent Claim
8 words
A compound according to claim 2, namely 7β-[2-(2-amino-5-chlorothiazol-4-yl)-2(Z)-methoxyiminoacetamido]-3-[(pyrazolo[1,5-a]pyridinium-3-yl)methyl]-3-cephem-4-carboxylate.
Claim 10
Dependent Claim
8 words
A compound according to claim 2, namely 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-methoxyiminoacetamido]-3-[(pyrazolo[1,5-a]pyridinium-3-yl)methyl]-3-cephem-4-carboxylate.
Claim 11
Dependent Claim
8 words
A compound according to claim 2, namely 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-[(pyrazolo[1,5-a]pyridinium-3-yl)methyl]-3-cephem-4-carboxylate.
Claim 12
Dependent Claim
30 words
A pharmaceutical composition produced by mixing at least one of the cephem compounds claimed in claim 1, or physiologically or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers or excipients.
Claim 13
Dependent Claim
19 words
A pharmaceutical composition produced by mixing the cephem compound of claim 3 and a pharmaceutically acceptable carrier or excipient.
Claim 14
Dependent Claim
19 words
A pharmaceutical composition produced by mixing the cephem compound of claim 4 and a pharmaceutically acceptable carrier or excipient.
Claim 15
Dependent Claim
19 words
A pharmaceutical composition produced by mixing the cephem compound of claim 5 and a pharmaceutically acceptable carrier or excipient.
Claim 16
Dependent Claim
19 words
A pharmaceutical composition produced by mixing the cephem compound of claim 6 and a pharmaceutically acceptable carrier or excipient.
Claim 17
Dependent Claim
19 words
A pharmaceutical composition produced by mixing the cephem compound of claim 7 and a pharmaceutically acceptable carrier or excipient.
Claim 18
Dependent Claim
19 words
A pharmaceutical composition produced by mixing the cephem compound of claim 8 and a pharmaceutically acceptable carrier or excipient.
Claim 19
Dependent Claim
19 words
A pharmaceutical composition produced by mixing the cephem compound of claim 9 and a pharmaceutically acceptable carrier or excipient.
References Cited (Backward Citations)
US4024133A
Cited
US4033950A
Cited
US4098888A
Cited
US4278671A
Cited
US4278793A
Cited
US4258041A
Cited
GB2037281A
Cited
EP0062321A2
Cited
US4501739A
Cited
US4500526A
Cited
EP0149487A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-11 | 1990-11-10 | 1991-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-11 | 1994-11-10 | 1995-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-11 | 1998-11-10 | 1999-05-12 | $7700.00 | Window Closed / Lapsed |